[38] discovered that inhibiting soluble epoxide hydrolase can enhance cancer immunotherapy outcomes, reinforcing our belief that targeting EPHX2‐dependent pathways may be a promising therapeutic strategy. This evidence concerns the gene EPHX2 and cancer.